Bank of Montreal Can Acquires 100,177 Shares of BioNTech SE (NASDAQ:BNTX)

Bank of Montreal Can boosted its holdings in BioNTech SE (NASDAQ:BNTXGet Rating) by 361.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 127,906 shares of the company’s stock after acquiring an additional 100,177 shares during the quarter. Bank of Montreal Can owned 0.05% of BioNTech worth $23,342,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Synovus Financial Corp increased its stake in BioNTech by 15.4% in the fourth quarter. Synovus Financial Corp now owns 2,990 shares of the company’s stock valued at $771,000 after acquiring an additional 400 shares during the period. Exane Derivatives increased its stake in BioNTech by 18.1% in the first quarter. Exane Derivatives now owns 704 shares of the company’s stock valued at $120,000 after acquiring an additional 108 shares during the period. Primecap Management Co. CA increased its stake in BioNTech by 1.3% in the first quarter. Primecap Management Co. CA now owns 4,242,068 shares of the company’s stock valued at $723,527,000 after acquiring an additional 54,950 shares during the period. Bank of America Corp DE grew its stake in BioNTech by 33.5% during the fourth quarter. Bank of America Corp DE now owns 84,826 shares of the company’s stock worth $21,868,000 after buying an additional 21,272 shares during the last quarter. Finally, Marshall Wace LLP grew its stake in BioNTech by 6,301.8% during the fourth quarter. Marshall Wace LLP now owns 169,007 shares of the company’s stock worth $43,321,000 after buying an additional 166,367 shares during the last quarter. Institutional investors own 13.77% of the company’s stock.

BioNTech Trading Up 0.1 %

Shares of NASDAQ BNTX opened at $147.90 on Friday. The company’s 50 day simple moving average is $157.64 and its 200 day simple moving average is $155.57. BioNTech SE has a fifty-two week low of $117.08 and a fifty-two week high of $374.85. The firm has a market capitalization of $35.89 billion, a P/E ratio of 2.86 and a beta of -0.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.15 and a quick ratio of 5.06.

BioNTech (NASDAQ:BNTXGet Rating) last announced its quarterly earnings data on Monday, August 8th. The company reported $6.45 earnings per share for the quarter, missing the consensus estimate of $7.08 by ($0.63). BioNTech had a net margin of 55.43% and a return on equity of 88.76%. The business had revenue of $3.20 billion during the quarter, compared to analyst estimates of $4.11 billion. During the same quarter in the prior year, the company earned $12.98 earnings per share. The company’s quarterly revenue was down 39.8% on a year-over-year basis. On average, analysts predict that BioNTech SE will post 33.37 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. The Goldman Sachs Group set a $200.00 price objective on shares of BioNTech in a research note on Tuesday, August 9th. Deutsche Bank Aktiengesellschaft set a $180.00 price objective on shares of BioNTech in a research note on Friday, July 1st. UBS Group set a $168.00 target price on shares of BioNTech in a research report on Thursday, June 30th. Canaccord Genuity Group reiterated a “buy” rating and set a $192.00 target price on shares of BioNTech in a research report on Wednesday, July 6th. Finally, SVB Leerink upped their target price on shares of BioNTech from $223.00 to $224.00 and gave the stock an “outperform” rating in a research report on Friday, July 29th. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, BioNTech presently has an average rating of “Hold” and an average price target of $231.43.

BioNTech Profile

(Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

Featured Articles

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE (NASDAQ:BNTXGet Rating).

Institutional Ownership by Quarter for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.